Fair Value (Details)
|
|
1 Months Ended |
3 Months Ended |
12 Months Ended |
|
|
|
|
|
|
Jun. 09, 2020
USD ($)
|
Jun. 30, 2020
USD ($)
|
Mar. 31, 2022
$ / shares
|
Dec. 31, 2021
USD ($)
$ / shares
shares
|
Dec. 31, 2021
CAD ($)
|
Dec. 31, 2020
USD ($)
|
Oct. 05, 2021
USD ($)
|
Apr. 01, 2021
shares
|
Oct. 30, 2020
$ / shares
|
Jun. 30, 2020
CAD ($)
|
Feb. 08, 2018
$ / shares
shares
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Convertible Debt | $ |
$ 17,000,000
|
|
|
|
|
|
$ 20,000,000
|
|
|
|
|
| Purchase price | $ |
$ 15,000,000
|
|
|
|
|
|
$ 18,000,000
|
|
|
|
|
| Maturity date |
Oct. 05, 2021
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
5,750,000
|
| Purchase price per unit (in Dollars per share) | $ / shares |
|
|
|
$ 10
|
|
|
|
|
|
|
$ 10
|
| Shares sold (in Shares) | shares |
|
|
|
243,750
|
|
|
|
|
|
|
750,000
|
| Exercise price (in Dollars per share) | $ / shares |
|
|
|
$ 11.5
|
|
|
|
|
|
|
|
| Exchange ratio of converted warrants upon conversion |
|
|
1
|
|
|
|
|
|
|
|
|
| Description of contingent consideration |
|
|
|
i) $0.01 per solo*TAGTM and solo*CODETM sold or (ii) 7% of net revenue. The fees were to be paid annually
until the earlier of: (1) our shares trading above $12 per share for any consecutive 20 trading days in a 30-day period; (b) upon our
no longer owning a majority stake in Solo; or (c) upon expiration of the patents related to solo*TAGTM and solo*CODETM, which is December
1, 2029.
|
i) $0.01 per solo*TAGTM and solo*CODETM sold or (ii) 7% of net revenue. The fees were to be paid annually
until the earlier of: (1) our shares trading above $12 per share for any consecutive 20 trading days in a 30-day period; (b) upon our
no longer owning a majority stake in Solo; or (c) upon expiration of the patents related to solo*TAGTM and solo*CODETM, which is December
1, 2029.
|
|
|
|
|
|
|
| Fair value of the contingent consideration | $ |
|
|
|
$ 6,300,000
|
|
|
|
|
|
|
|
| Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued (in Shares) | shares |
|
|
|
189,365
|
|
|
|
|
|
|
|
| Purchase price per unit (in Dollars per share) | $ / shares |
|
|
|
|
|
|
|
|
$ 2.4
|
|
|
| Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
189,365
|
| Private Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Exercise price (in Dollars per share) | $ / shares |
|
|
$ 11.5
|
$ 11.5
|
|
|
|
|
|
|
|
| Solo Sciences, Inc. [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Fair value of the contingent consideration | $ |
|
|
|
$ 389,000
|
|
|
|
|
|
|
|
| Settled value of the contingent consideration | $ |
|
|
|
0
|
|
|
|
|
|
|
|
| Gain on settlement of the contingent consideration liability | $ |
|
|
|
389,000
|
|
|
|
|
|
|
|
| Trellis Solutions, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Fair value of the contingent consideration | $ |
|
$ 998,000
|
|
$ 998,000
|
|
|
|
|
|
|
|
| Settled value of the contingent consideration | $ |
|
$ 0
|
|
|
|
|
|
|
|
|
|
| Ample Organics [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Description of contingent consideration |
|
|
|
The contingent consideration amount is reduced by an amount equal to the product of CAD$6.67 multiplied
by the difference between CAD$9,000,000and the amount of Recurring Revenue realized during the twelve months following the acquisition.
|
The contingent consideration amount is reduced by an amount equal to the product of CAD$6.67 multiplied
by the difference between CAD$9,000,000and the amount of Recurring Revenue realized during the twelve months following the acquisition.
|
|
|
|
|
|
|
| Fair value of the contingent consideration |
|
|
|
$ 604,000
|
|
|
|
|
|
$ 10,000,000
|
|
| Settled value of the contingent consideration | $ |
|
|
|
|
|
$ 0
|
|
|
|
|
|
| Gain on settlement of the contingent consideration liability | $ |
|
|
|
|
|
$ 604,000
|
|
|
|
|
|
| Recurring revenue recognized (in Dollars) | $ |
|
|
|
|
$ 9,000,000
|
|
|
|
|
|
|
| Viridian Member |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Fair value of the contingent consideration | $ |
|
|
|
2,000
|
|
|
|
|
|
|
|
| Viridian Sciences [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Shares sold (in Shares) | shares |
|
|
|
|
|
|
|
1,000,000
|
|
|
|
| Fair value of the contingent consideration | $ |
|
|
|
2,000
|
|
|
|
|
|
|
|
| 365 Cannabis [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Fair value of the contingent consideration | $ |
|
|
|
$ 6,300,000
|
|
|
|
|
|
|
|
| MTech [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Exercise price (in Dollars per share) | $ / shares |
|
|
|
$ 11.5
|
|
|
|
|
|
|
|
| MTech [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
5,750,000
|
| MTech [Member] | Public Warrant [Member] | IPO [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Purchase price per unit (in Dollars per share) | $ / shares |
|
|
|
|
|
|
|
|
|
|
$ 10
|
| Number of securities called by each warrant or right (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
1
|
| Exercise price (in Dollars per share) | $ / shares |
|
|
|
|
|
|
|
|
|
|
$ 11.5
|
| MTech [Member] | Public Warrant [Member] | Over-Allotment Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Shares sold (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
750,000
|
| MTech [Member] | Public Warrant [Member] | Common Stock [Member] | IPO [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Number of securities called by each warrant or right (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
1
|
| MTech [Member] | Public Warrant [Member] | Warrant [Member] | IPO [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Number of securities called by each warrant or right (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
1
|
| MTech [Member] | Private Warrant [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Purchase price per unit (in Dollars per share) | $ / shares |
|
|
|
|
|
|
|
|
|
|
$ 10
|
| Shares sold (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
243,750
|
| Number of securities called by each warrant or right (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
1
|
| Exercise price (in Dollars per share) | $ / shares |
|
|
|
|
|
|
|
|
|
|
$ 11.5
|
| MTech [Member] | Private Warrant [Member] | Common Stock [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Number of securities called by each warrant or right (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
1
|
| MTech [Member] | Private Warrant [Member] | Warrant [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
| Fair Value (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
| Number of securities called by each warrant or right (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
1
|